Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 22 (9), 1193-9

Tofacitinib in Kidney Transplantation

Affiliations
Review

Tofacitinib in Kidney Transplantation

David Wojciechowski et al. Expert Opin Investig Drugs.

Abstract

Introduction: This review will discuss the mechanism of action and important kidney transplant clinical trial data for the small molecule Janus kinase (JAK) 3 inhibitor tofacitinib , formerly known as CP-690,550 and tasocitinib.

Areas covered: Successful kidney transplantation requires adequate immunosuppression. Current maintenance immunosuppressive protocols which rely on calcineurin inhibitors have long-term nephrotoxicity and negative impact on cardiometabolic risk factors. JAKs are cytoplasmic tyrosine kinases that participate in the signaling of a broad range of cell surface receptors, particularly members of the cytokine receptor common gamma (cγ) chain family. JAK3 inhibition has immunosuppressive effects and treatment with tofacitinib in clinical trials has demonstrated efficacy in autoimmune disorders such as psoriasis and rheumatoid arthritis. Nonhuman primate models of renal transplantation demonstrated prolonged graft survival with tofacitinib compared to control. Renal transplant clinical trials in humans have demonstrated tofacitinib to be noninferior to cyclosporine in terms of rejection rates and graft survival. There was also a lower rate of new onset diabetes after transplant. However, there was a trend toward more infections, including cytomegalovirus and BK virus nephritis.

Expert opinion: Tofacitinib may be a promising alternative to calcineurin inhibitors. The optimal therapeutic window is still being determined.

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

  • Impact of Immune-Modulatory Drugs on Regulatory T Cell
    A Furukawa et al. Transplantation 100 (11), 2288-2300. PMID 27490409. - Review
    Immunosuppression strategies that selectively inhibit effector T cells while preserving and even enhancing CD4FOXP3 regulatory T cells (Treg) permit immune self-regulatio …
  • Novel Therapies for Memory Cells in Autoimmune Diseases
    P Bhargava et al. Clin Exp Immunol 180 (3), 353-60. PMID 25682849. - Review
    Autoimmune diseases are a major cause of morbidity, and their incidence and prevalence continue to rise. Treatments for these diseases are non-specific and result in sign …
  • What's New in Clinical Solid Organ Transplantation by 2013
    M Salvadori et al. World J Transplant 4 (4), 243-66. PMID 25540734. - Review
    Innovative and exciting advances in the clinical science in solid organ transplantation continuously realize as the results of studies, clinical trials, international con …

MeSH terms

LinkOut - more resources

Feedback